Leaflet: information for the user
Fampyra 10 mg prolonged-release tablets
fampridina
Read this leaflet carefully before you start taking this medicine, because it contains important information for you.
Fampyra is a medication used to improve walking in adults (18 years of age or older) with multiple sclerosis (MS) who have walking disability. In multiple sclerosis, inflammation destroys the protective covering of nerves, leading to muscle weakness, muscle stiffness, and difficulty walking.
Fampyra contains the active ingredient fampridine, which belongs to a group of medications called potassium channel blockers. They work by slowing the release of potassium from damaged nerve cells caused by MS. It is believed that this medication acts by allowing signals to pass through the nerve in a more normal way, enabling better walking.
Do not take Fampyra
Inform your doctoranddo not takeFampyra if any of these situations apply to you.
Warnings and precautions
Consult your doctor or pharmacist before starting to take Fampyra:
Inform your doctor beforetaking Fampyra if any of these situations apply to you.
Children and adolescents
Do not administer Fampyra to children or adolescents under 18 years old.
Older adults
Before starting treatment and during treatment, your doctor may check that your kidneys are functioning correctly.
Taking Fampyra with other medications
Inform your doctor or pharmacistif you are using or have used recently or may need to useany other medication.
Do not take Fampyra if you are taking other medications that contain fampridina.
Other medications that affect the kidneys
Your doctor will take special care if you receive fampridina at the same time as another medication that may affect the elimination of other medications by the kidneys, for example carvedilol, propranolol, and metformin.
Taking Fampyra with food and drinks
Fampyra should be taken without food, on an empty stomach.
Pregnancy and breastfeeding
If you are pregnantor intend to become pregnant,consult your doctor beforeusingthis medication.
This medication is not recommended during pregnancy.
Your doctor will evaluate the benefit of treatment with Fampyra for you against the risk to the baby.
You must interrupt breastfeedingduring treatment with this medication.
Driving and operating machinery
Fampyra may affect people's ability to drive and operate machinery, causing dizziness. Make sure it does not affect you before starting to drive or operate machinery.
Follow exactly the administration instructions for this medication as indicated by your doctor. In case of doubt, consult your doctor or pharmacist again. Fampyra can only be obtained with a prescription and under the supervision of experienced EM doctors.
Your doctor will initially prescribe treatment for 2 to 4 weeks. After this 2 to 4 week period, your treatment will be re-evaluated.
The recommended dose is
One tablet in the morning and one tablet at night (12 hours apart). Do not take more than two tablets in a day. You must allow 12 hours to pass between each tablet. Do not take the tablets more frequently than every 12 hours.
Swallow the tablet whole, with water. Do not divide, crush, dissolve, suck, or chew the tablet. This could increase the risk of adverse effects.
If your Fampyra is presented in bottles, the bottle will also contain a desiccant. Leave the desiccant in the bottle, do not ingest it.
If you take more Fampyra than you should
Immediately contact your doctor if you take too many tablets.
If you visit your doctor, bring the Fampyra box with you.
If you experience an overdose
You may notice sweating, small tremors ( shaking , dizziness, confusion, memory loss ( amnesia ), and seizures ( epileptic crises ). You may also notice other effects not mentioned here.
If you forget to take Fampyra
If you forget to take a tablet , do not take a double dose to compensate for the missed doses.
Always allow 12 hours to pass between each tablet.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, Fampyra can cause side effects, although not everyone will experience them.
If you have a seizure, stop taking Fampyraand inform your doctor immediately.
If you experience one or more of the following allergic symptoms (hypersensitivity): swelling of the face, mouth, lips, throat, or tongue, redness or itching of the skin, chest tightness, and breathing problems,stop taking Fampyraandseekmedical attention immediately.
The following side effects are listed by frequency:
Very common side effects
May affect more than 1 in 10 people:
May affect up to 1 in 10 people:
Uncommon side effects
May affect up to 1 in 100 people:
Reporting of side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect not listed in this leaflet. You can also report them directly through thenational notification system included in theAppendixV*. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the packaging after CAD. The expiration date is the last day of the month indicated.
Store below 25°C. Store the tablets in the original packaging to protect them from light and moisture.
If Fampyra is presented in bottles, only open one bottle at a time. After the first opening of the bottle, use within 7 days.
Medicines should not be thrown down the drains or in the trash. Ask your pharmacist how to dispose of the packaging and the medication that you no longer need. This will help protect the environment.
Composition of Fampyra
You can obtain a larger print version of this leaflet by calling the local representatives (see list below).
Composition of Fampyra
stearate of magnesium; film coating: Hypromellose, titanium dioxide (E-171), Macrogol 400
Appearance of the product and contents of the pack
Fampyra is a prolonged-release tablet, 13 x 8 mm, oval, biconvex, white, with A10 engraved on one side.
Fampyra is presented in blister packs or bottles
Bottles
Fampyra is presented in HDPE (high-density polyethylene) bottles. Each bottle contains
14 tablets and a silica gel desiccant. Each pack contains 28 tablets (2 bottles) or
56 tablets (4 bottles).
Blister packs
Fampyra is presented in blister packs of 14 tablets each. Each pack contains 28 tablets (2 blister packs) or 56 tablets (4 blister packs).
Only some sizes or presentations of packs may be marketed.
Marketing authorisation holder and manufacturer
Marketing authorisation holder:
Acorda Therapeutics Ireland Limited
10 Earlsfort Terrace
Dublin 2, D02 T380
Ireland
Tel: +353 (0)1 231 4609
Manufacturer:
Novo Nordisk Production Ireland Limited, Monksland, Athlone, Co. Westmeath, Ireland
Patheon France SAS, 40 Boulevard de Champaret, 38300 Bourgoin Jallieu, France.
You can request more information about this medicine by contacting the local representative of the marketing authorisation holder:
Belgium/Belgique/Belgien Acorda Therapeutics Ireland Limited 10 Earlsfort Terrace Dublin 2, D02 T380 Ireland/Irlande/Irland Tel: +353 (0)1 231 4609 | Lithuania Acorda Therapeutics Ireland Limited 10 Earlsfort Terrace Dublin 2, D02 T380 Ireland Tel: +353 (0)1 231 4609 |
Luxembourg/Luxemburg Acorda Therapeutics Ireland Limited 10 Earlsfort Terrace Dublin 2, D02 T380 Ireland/Irland Tel: +353 (0)1 231 4609 | |
Czech Republic Acorda Therapeutics Ireland Limited 10 Earlsfort Terrace Dublin 2, D02 T380 Ireland Tel: +353 (0)1 231 4609 | Hungary Acorda Therapeutics Ireland Limited 10 Earlsfort Terrace Dublin 2, D02 T380 Ireland Tel: +353 (0)1 231 4609 |
Denmark Merz Therapeutics Nordics AB Gustav III S Boulevard 32 Regus Solna 169 73 Sweden Tlf.: +46 8 368000 | Malta Acorda Therapeutics Ireland Limited 10 Earlsfort Terrace Dublin 2, D02 T380 Ireland Tel: +353 (0)1 231 4609 |
Germany Merz Therapeutics GmbH Eckenheimer Landstrasse 100 60318 Frankfurt Tel: +49 (0) 69 15 03 0 | Netherlands Acorda Therapeutics Ireland Limited 10 Earlsfort Terrace Dublin 2, D02 T380 Ireland Tel: +353 (0)1 231 4609 |
Estonia Acorda Therapeutics Ireland Limited 10 Earlsfort Terrace Dublin 2, D02 T380 Ireland Tel: +353 (0)1 231 4609 | Norway Merz Therapeutics Nordics AB Gustav III S Boulevard 32 Regus Solna 169 73 Sweden Tlf.: +46 8 368000 |
Greece Acorda Therapeutics Ireland Limited 10 Earlsfort Terrace Dublin 2, D02 T380 Ireland Tel: +353 (0)1 231 4609 | Austria Merz Pharma Austria GmbH Guglgasse 17 1110 Vienna Tel: +43 (0) 1 865 88 95 |
Spain Merz Therapeutics Iberia S.L. Avenida de Bruselas 6 28108 Alcobendas Madrid Tel: +34 91 117 8917 | Poland Acorda Therapeutics Ireland Limited 10 Earlsfort Terrace Dublin 2, D02 T380 Ireland Tel: +353 (0)1 231 4609 |
France Merz Pharma France Tour EQHO 2, Avenue Gambetta 92400 Courbevoie Tel: +33 1 47 29 16 77 | Portugal Merz Therapeutics Iberia S.L. Avenida de Bruselas 6 28108 Alcobendas Madrid Tel: +34 91 117 8917 |
Croatia Acorda Therapeutics Ireland Limited 10 Earlsfort Terrace Dublin 2, D02 T380 Ireland Tel: +353 (0)1 231 4609 | Romania Acorda Therapeutics Ireland Limited 10 Earlsfort Terrace Dublin 2, D02 T380 Ireland Tel: +353 (0)1 231 4609 |
Ireland Merz Pharma UK Ltd. Suite B, Breakspear Park, Breakspear Way Hemel Hempstead Hertfordshire HP2 4TZ United Kingdom Tel: +44 (0)208 236 0000 | Slovenia Acorda Therapeutics Ireland Limited 10 Earlsfort Terrace Dublin 2, D02 T380 Ireland Tel: +353 (0)1 231 4609 |
Iceland Acorda Therapeutics Ireland Limited 10 Earlsfort Terrace Dublin 2, D02 T380 Ireland Tel: +353 (0)1 231 4609 | Slovakia Acorda Therapeutics Ireland Limited 10 Earlsfort Terrace Dublin 2, D02 T380 Ireland Tel: +353 (0)1 231 4609 |
Italy Merz Pharma Italia Srl Via Fabio Filzi 25 A 20124 Milan Tel: +39 02 66 989 111 | Finland/Suomi Acorda Therapeutics Ireland Limited 10 Earlsfort Terrace Dublin 2, D02 T380 Ireland/Irland Tel: +353 (0)1 231 4609 |
Cyprus Acorda Therapeutics Ireland Limited 10 Earlsfort Terrace Dublin 2, D02 T380 Ireland Tel: +353 (0)1 231 4609 | Sweden Merz Therapeutics Nordics AB Gustav III S Boulevard 32 Regus Solna 169 73 Tel: +46 8 368000 |
Lithuania Acorda Therapeutics Ireland Limited 10 Earlsfort Terrace Dublin 2, D02 T380 Ireland Tel: +353 (0)1 231 4609 |
Last update of this leaflet: {monthYYYY}.
More detailed information about this medicine is available on the website of the European Medicines Agency:http://www.ema.europa.eu/.
Маєте питання щодо цього лікування або ваших симптомів? Зв'яжіться з ліцензованим лікарем для отримання допомоги та персонального догляду.